1
|
Park SS, Sanders DB, Smith BP, Ryan J, Plasencia J, Osborn MB, Wellnitz CM, Southard RN, Pierce CN, Arabia FA, Lane J, Frakes D, Velez DA, Pophal SG, Nigro JJ. Total artificial heart in the pediatric patient with biventricular heart failure. Perfusion 2013; 29:82-8. [PMID: 23868320 DOI: 10.1177/0267659113496580] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Mechanical circulatory support emerged for the pediatric population in the late 1980s as a bridge to cardiac transplantation. The Total Artificial Heart (TAH-t) (SynCardia Systems Inc., Tuscon, AZ) has been approved for compassionate use by the Food and Drug Administration for patients with end-stage biventricular heart failure as a bridge to heart transplantation since 1985 and has had FDA approval since 2004. However, of the 1,061 patients placed on the TAH-t, only 21 (2%) were under the age 18. SynCardia Systems, Inc. recommends a minimum patient body surface area (BSA) of 1.7 m(2), thus, limiting pediatric application of this device. This unique case report shares this pediatric institution's first experience with the TAH-t. A 14-year-old male was admitted with dilated cardiomyopathy and severe biventricular heart failure. The patient rapidly decompensated, requiring extracorporeal life support. An echocardiogram revealed severe biventricular dysfunction and diffuse clot formation in the left ventricle and outflow tract. The decision was made to transition to biventricular assist device. The biventricular failure and clot formation helped guide the team to the TAH-t, in spite of a BSA (1.5 m(2)) below the recommendation of 1.7 m(2). A computed tomography (CT) scan of the thorax, in conjunction with a novel three-dimensional (3D) modeling system and team, assisted in determining appropriate fit. Chest CT and 3D modeling following implantation were utilized to determine all major vascular structures were unobstructed and the bronchi were open. The virtual 3D model confirmed appropriate device fit with no evidence of compression to the left pulmonary veins. The postoperative course was complicated by a left lung opacification. The left lung anomalies proved to be atelectasis and improved with aggressive recruitment maneuvers. The patient was supported for 11 days prior to transplantation. Chest CT and 3D modeling were crucial in assessing whether the device would fit, as well as postoperative complications in this smaller pediatric patient.
Collapse
Affiliation(s)
- S S Park
- 1Division of Cardiothoracic Surgery, Division of Cardiology, Division of Critical Care Medicine, Children's Heart Center, Division of Radiology, Phoenix Children's Hospital, Phoenix, AZ, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Abstract
The Fontan procedure represents the final stage of the transition to single ventricle physiology. Conversion of very complex congenital heart anatomy, such as hypoplastic left heart syndrome, double-outlet right ventricle or double-inlet left ventricle, to a single ventricle has grown in popularity as morbidity and mortality have improved. As these patients grow, survivors are at risk for impaired ventricular dysfunction, plastic bronchitis, protein-losing enteropathy and late failure. Late failing Fontan patients represent a particularly vexing scenario for clinicians, as the only durable treatment option is cardiac transplantation. However, in the short-term, some of these patients require support beyond medical management, with mechanical circulatory support via extracorporeal life support or a ventricular assist device. We report the successful bridge of an adolescent female post-Fontan conversion with late severe cardiac failure. The patient was initially resuscitated with extracorporeal life support, transitioned to a single Berlin Heart EXCOR® ventricular assist device and, subsequently, underwent successful cardiac transplantation.
Collapse
Affiliation(s)
- DB Sanders
- Scott and Laura Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA
- Children’s Heart Center, Phoenix Children’s Hospital, Phoenix, AZ, USA
| | - SR Sowell
- Scott and Laura Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA
- Children’s Heart Center, Phoenix Children’s Hospital, Phoenix, AZ, USA
| | - SS Park
- Scott and Laura Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA
- Children’s Heart Center, Phoenix Children’s Hospital, Phoenix, AZ, USA
| | - C Derby
- Scott and Laura Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA
- Children’s Heart Center, Phoenix Children’s Hospital, Phoenix, AZ, USA
- Cardon Children’s Hospital, Banner Desert Hospital, Mesa, AZ, USA
| | - BC Willis
- Scott and Laura Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA
- Children’s Heart Center, Phoenix Children’s Hospital, Phoenix, AZ, USA
| | - JE Lane
- Scott and Laura Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA
- Children’s Heart Center, Phoenix Children’s Hospital, Phoenix, AZ, USA
| | | | | | - SG Pophal
- Scott and Laura Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA
- Children’s Heart Center, Phoenix Children’s Hospital, Phoenix, AZ, USA
| | - JJ Nigro
- Scott and Laura Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA
- Children’s Heart Center, Phoenix Children’s Hospital, Phoenix, AZ, USA
| |
Collapse
|
3
|
Nolan PE, Arabia FA, Smith RG, Sethi GK, Bose RK, Banchy ME, Woolley DS, Rhenman BE, McCarthy MS, Copeland JG. STROKE OUTCOMES FOLLOWING IMPLANTATION OF THE CAR-DIOWEST TOTAL ARTIFICIAL HEART. ASAIO J 2002. [DOI: 10.1097/00002480-200203000-00084] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
4
|
Abstract
BACKGROUND In the past, explantation of the Cardio West total artificial heart (TAH) has been technically challenging because of the presence of dense adhesions and extremely thickened pericardium. To prevent this, we constructed a synthetic neo-pericardium in 14 patients. METHODS Using expanded polytetrafluoroethylene (e-PTFE) membrane, we constructed a pericardium within the pericardium, or "neo-pericardium," completely covering the Cardio West TAH separating the native atria from the native pericardium, and wrapping the ascending aorta from the outflow conduit distally for about 5 to 7 cm. RESULTS Of the 14 patients, 9 were transplanted and could be evaluated, 3 died on device support, and 2 are currently on device support. In each case, we attained faster (by 25 minutes) and easier reentry through the sternum. Surgical planes around the aorta, over the right and left atria, and throughout the pericardial space became apparent immediately after e-PTFE membrane removal. The pericardium and related tissues although slightly thickened (<2 mm) were pliable compared with our previous 36 patients, with very thick adherent pericardium over the device and native atria. CONCLUSIONS The plastic materials forming the ventricular housing and drivelines of the Cardio West TAH and the Dacron outflow conduits have in the past caused profound local inflammatory reactions, resulting in extremely dense adhesions and thickened adherent pericardium. Using e-PTFE membrane to fashion a complete neo-pericardium and to wrap the ascending aorta at the time of Cardio West implantation dramatically reduces adhesions and pericardial thickening and facilitates explantation.
Collapse
Affiliation(s)
- J G Copeland
- University of Arizona Sarver Heart Center, Tucson, Arizona 85724, USA.
| | | | | | | |
Collapse
|
5
|
Abstract
There has been a quest for an artificial organ that can replace the heart for decades. Remarkable advances were made in the second half of the twentieth century in the fields of medicine and engineering that led to the development of several devices with the intention of totally replacing the human heart. Some of these devices, like the Jarvik artificial heart, were utilized initially as a permanent replacement for the failing heart. It became more successful as a bridge to heart transplantation (BTT) in the years that followed its introduction. Currently the CardioWest total artificial heart (TAH) is the only device in clinical use with the intention of bridging patients to heart transplantation. Two new TAHs are being developed with the intention of being used as an alternative to transplantation (ATT) or on a permanent basis. The next 100 years will bring revolutionary new designs and advances in the field of end stage heart disease that may only be ideas at the present time.
Collapse
Affiliation(s)
- F A Arabia
- The Marshall Foundation Artificial Heart Program, University of Arizona Sarver Heart Center, Tucson, USA.
| |
Collapse
|
6
|
Abstract
A Thoratec left ventricular assist device (LVAD) was used to support a 7-year-old 17-kg boy with viral cardiomyopathy for 23 days before heart transplantation. The boy is still living more than 1 year posttransplant, and functional except for some spastic paresis of the left hand, a residual from a stroke during device support. He is the smallest person to be supported with this device. We discuss techniques for using the Thoratec in children.
Collapse
Affiliation(s)
- J G Copeland
- Section of Cardiovascular and Thoracic Surgery and Artificial Heart Program, University Medical Center, University of Arizona, Tucson, USA.
| | | | | |
Collapse
|
7
|
Copeland JG, Smith RG, Arabia FA, Nolan PE, Mehta VK, McCarthy MS, Chisholm KA. Comparison of the CardioWest total artificial heart, the novacor left ventricular assist system and the thoratec ventricular assist system in bridge to transplantation. Ann Thorac Surg 2001; 71:S92-7; discussion S114-5. [PMID: 11265873 DOI: 10.1016/s0003-4975(00)02625-4] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND Device selection has historically been supported by minimal comparative data. Since 1994, we have implanted 43 patients with the CardioWest Total Artificial Heart (CW), 23 with the Novacor Left Ventricular Assist System (N), and 26 with the Thoratec Ventricular Assist System (T). This experience provides a basis for our device selection criteria. METHODS We reviewed retrospectively the results for survival, stroke, and infection in the CW, N, and T groups. Statistical methods included the Student's t-test, chi2 analysis, and Kaplan-Meier actuarial survival curves. RESULTS The T group patients were younger and smaller sized than the CW or N group. The CW group had the highest mean central venous pressure (CVP) and lowest mean cardiac index. Survival to transplantation was 75% for CW, 57% for N, and 38% for T. Multiple organ failure postimplant caused most deaths in the CW and T groups. Right heart failure and stroke caused most N deaths. Linearized stroke rates (event/patient-month) were 0.03 for CW, 0.28 for N, and 0.08 for T. Serious infections were found in 20% of CW, 30% of N, and 8% of T patients, but linearized rates showed little difference and death from infection was rare. CONCLUSIONS The N device should be used in "stable" patients with body surface area (BSA) greater than 1.7 m2 and with minimal right heart failure. Unstable patients with biventricular failure should receive a CW if the BSA is greater than 1.7 m2 or a T if they are smaller.
Collapse
Affiliation(s)
- J G Copeland
- University of Arizona Sarver Heart Center, Tucson, Arizona 85724-5071, USA.
| | | | | | | | | | | | | |
Collapse
|
8
|
Abstract
The CardioWest total artificial heart (TAH), formerly known as the Jarvik-7 and then the Symbion heart, is the only TAH in current clinical use. A new study, approved by the Food and Drug Administration (FDA), was initiated in 1993 with the goal of approving this pump for commercial release. Since then, 145 CardioWest TAHs have been implanted, including 37 pumps in 36 patients at our center. Our 36 patients were studied prospectively according to the investigational device exemption protocol approved by the FDA. Clinical and hemodynamic data obtained upon patients' entry into the study identified this group as mortally ill. After receiving a CardioWest TAH, 29 of the 36 patients (81%) survived to heart transplantation, and 26 (72% of the total group and 90% of the transplant recipients) have survived for up to 7 years (average, 24 months). Multicomponent anticoagulation, based on readily available tests, and the intrinsic properties of the TAH have resulted in a low linearized stroke rate of 0.48 event per patient-year. There have been no device-related mediastinal infections. In dying patients with nonexistent or severely compromised biventricular function, the CardioWest TAH has proved safe and effective, allowing a 72% survival rate for an average of 24 months.
Collapse
Affiliation(s)
- J G Copeland
- The Marshall Foundation Artificial Heart Program, University of Arizona Sarver Heart Center, Tucson, USA
| | | | | | | | | |
Collapse
|
9
|
Wegner JA, DiNardo JA, Arabia FA, Copeland JG. Blood loss and transfusion requirements in patients implanted with a mechanical circulatory support device undergoing cardiac transplantation. J Heart Lung Transplant 2000; 19:504-6. [PMID: 10808160 DOI: 10.1016/s1053-2498(00)00075-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Patients implanted with mechanical circulatory support devices (MCSD's) are at high risk for post-operative bleeding at cardiac transplantation. However, the magnitude of the risk and transfusion requirements for MCSD patients at the time of transplantation have not been previously reported. The purpose of this study was to characterize and compare the bleeding characteristics and transfusion requirements of 3 sub-groups of cardiac transplant patients: primary (n = 45), redo (n = 26), and MCSD (n = 23) patients.
Collapse
Affiliation(s)
- J A Wegner
- University of Arizona Sarver Heart Center, Tucson, USA
| | | | | | | |
Collapse
|
10
|
Abstract
BACKGROUND We hypothesized that bridge to transplantation with the CardioWest Total Artificial Heart would succeed in a large percentage of patients. Further, we hypothesized that this success rate would not be significantly decreased by infection or thromboembolism. METHODS From 1993 to March 1999, 24 patients received implants with the intention of bridge to transplantation. Data were collected prospectively. Heparin, coumadin, aspirin, ticlopidine, dipyridamole, and pentoxifylline were used for anticoagulation. RESULTS Four patients died while on device support. Nineteen of 23 patients (83%) were transplanted. All 19 survived long term. One patient remains on CardioWest Total Artificial Heart support 6 weeks after implant. There was one stroke on the day of transplantation. There was a second stroke on the day of implantation. Neither stroke caused significant residual deficits. Both were in close relationship to an operative procedure. There were no serious device-related infections. CONCLUSIONS The CardioWest Total Artificial Heart salvaged 20 of 24 critically ill patients. Neither infections nor neurologic problems were significant. We believe it is the device of choice for decompensating patients with biventricular failure who have adequate body and heart size.
Collapse
Affiliation(s)
- J G Copeland
- Cardiovascular and Thoracic Surgery, University of Arizona Health Sciences Center, Tucson 85724, USA.
| | | | | | | | | | | |
Collapse
|
11
|
Abstract
The CardioWest total artificial heart is a pneumatically driven device that totally replaces the failing ventricles. It is currently undergoing clinical investigation as a bridge to heart transplantation in several centers throughout the world. A bilateral ventriculectomy is performed and the device is implanted. Blood flows are usually maintained at 6-8 L/min. Approximately 130 patients have undergone bridge to transplant with this device. Patient selection and excellent surgical technique are required for a successful outcome. A detailed description of the implantation technique is presented to facilitate the use of this technology.
Collapse
Affiliation(s)
- F A Arabia
- University of Arizona Health Sciences Center, Tucson 85724-5071, USA.
| | | | | | | |
Collapse
|
12
|
Arabia FA, Copeland JG, Smith RG, Banchy M, Foy B, Kormos R, Tector A, Long J, Dembitsky W, Carrier M, Keon W, Pavie A, Duveau D. CardioWest total artificial heart: a retrospective controlled study. Artif Organs 1999; 23:204-7. [PMID: 10027892 DOI: 10.1046/j.1525-1594.1999.06270.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The CardioWest total artificial heart (TAH) is a pneumatic device that is used as a bridge to heart transplantation and the only TAH available that totally replaces the failing ventricles. It has been utilized in selected centers in the U.S.A. with approval from the Food and Drug Administration. Strict criteria have been developed to select candidates to be bridged with the TAH. The patient must be a heart transplant candidate of age >18 and <59 years with a body surface area (BSA) > or = 1.7 m2, cardiac index (CI) <2.0 L/min/m2, and 2 inotropic agents or 1 plus an intraaortic balloon pump (IABP). A total of 24 heat transplant candidates (Group A) met the entry criteria and underwent placement of the TAH between January 1993 and July 1996. Group A consisted of 23 males; 16 patients had an IABP. The control group (Group B) consisted of 18 heart transplant candidates who met the TAH entry criteria but never received a TAH. Group B consisted of 15 males; 14 patients had an IABP. Preimplantation pulmonary vascular resistance (PVR) (Wood units), serum creatinine (mg/dl), and total bilirubin (mg/dl) were determined in both groups. The mean values for Groups A and B were, respectively, age: 47 and 47 years, BSA: 2.01 and 1.93 m2, CI: 1.5 and 1.8 L/min/m2, PVR: 2.88 and 2.47 Wood units, creatinine: 1.5 and 1.6 mg/dl, and bilirubin: 1.8 and 1.4 mg/dl. In Group A, 1 patient died on the TAH, 1 patient died after transplant, and 22 patients reached transplant and were discharged home for a survival rate of 91.7%. In Group B, 10 patients died while waiting for a heart transplant. Of the 8 patients transplanted, 7 survived and were discharged home for a survival rate of 38.9% (p = 0.0003). In summary the CardioWest TAH provided an excellent and successful method of bridging patients to heart transplantation with a reasonable risk.
Collapse
Affiliation(s)
- F A Arabia
- Health Sciences Center, University of Arizona, Tucson 85724-5071, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
We present a technique for rapid and easy endomyocardial biopsy of the heterotopic transplanted heart. With a recent resurgence in heterotopic heart transplantation, we believe that ours is a sound technique in obtaining both routine surveillance biopsies as well as evaluating "right-sided pressures" in the "piggy-back" heart.
Collapse
Affiliation(s)
- D A Arzouman
- Section of Cardiovascular and Thoracic Surgery, University Heart Center, The University of Arizona Health Sciences Center, Tucson 85724, USA
| | | | | | | |
Collapse
|
14
|
Mussivand T, Kung RT, McCarthy PM, Poirier VL, Arabia FA, Portner P, Affeld K. Cost effectiveness of artificial organ technologies versus conventional therapy. ASAIO J 1997; 43:230-6. [PMID: 9152498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Affiliation(s)
- T Mussivand
- Cardiovascular Devices Division, University of Ottawa Heart Institute, Ontario, Canada
| | | | | | | | | | | | | |
Collapse
|
15
|
Arabia FA, Copeland JG, Smith RG, Sethi GK, Arzouman DA, Pavie A, Duveau D, Keon WJ, Masters R, Foy B, Carrier M, Dembitsky W, Long J, Kormos R. International experience with the CardioWest total artificial heart as a bridge to heart transplantation. Eur J Cardiothorac Surg 1997; 11 Suppl:S5-10. [PMID: 9271174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
As the number of potential heart donors remains constant and the number of potential recipients continuous to increase, the need for circulatory devices to bridge patients becomes more important. The CardioWest total artificial heart (TAH) is a pneumatic, implantable system that totally replaces the failing ventricles. It has been utilized worldwide as a bridge to heart transplantation in 79 patients. There were 73 males and six females who received the TAH. Currently three patients remain on the device waiting for transplantation. A total of 55 patients (70%) were transplanted of which 50 survived (91% of patients transplanted) and were discharged home. Idiopathic/dilated cardiomyopathy was the most common etiology followed by ischemic cardiomyopathy. The mean duration of implant was 34 days (range 0-186 days) and the mean age of the group was 45 years (range 16-62 years). Twenty-one patients died while on the device. Multiple organ failure was the major cause of death. There were a total of 255 complications in this group that included reoperation, bleeding, hepatic failure, renal failure, respiratory failure, neurologic events, thromboembolic events, infections, device malfunction, and fit complications. This represented a mean complication rate of three events per patient. The survival rate for the CardioWest TAH of 91% of the patients who reached transplantation is an improvement over that of the Symbion registry (55% of those transplanted) probably as a result of a better patient selection and better control of the coagulation system. These results are also comparable to those survival results obtained with other biventricular and left ventricular assist devices currently available.
Collapse
Affiliation(s)
- F A Arabia
- University of Arizona, Health Sciences Center, Tucson, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Arabia FA, Smith RG, Jaffe C, Wild JC, Rose DS, Nelson RJ, McClellan DM, Acuna GA, Edling NG, Harrington NK, Rabago G, Tsen AC, Arzouman DA, Sethi GK, Copeland JG. Cost analysis of the Novacor Left Ventricular Assist System as an outpatient bridge to heart transplantation. ASAIO J 1996; 42:M546-9. [PMID: 8944939 DOI: 10.1097/00002480-199609000-00046] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Three patients were bridged to heart transplantation with the wearable Novacor Left Ventricular Assist System (Baxter Healthcare Corp., Oakland, CA) (LVAS). Two have been transplanted and discharged. The third patient remains at home. Hospitalization costs, which include the unit room charge, admission profile to the unit, and daily supply charge, were determined for all patients and compared. The patients were transferred from the surgical intensive care unit to a telemetry unit once they were hemodynamically stable. The projected hospitalization costs, if the patients had remained in the hospital, were calculated to determine probable savings for the third party payer. The average period from admission to placement of the Novacor LVAS was 15 days (range, 7-21 days). The average hospitalization cost from admission to time of Novacor left ventricular assist device implant was $2,240/day, and the average hospitalization cost after implant to discharge was $1,570/day. Hospitalization cost savings were $2,632 for the first patient, $5,922 for the second patient, and $132,124 for the third patient, who has not been transplanted. Although the number of patients is small, the daily hospitalization cost was higher before the Novacor LVAS was implanted. This is related to the severity of the disease and the length of stay in a surgical intensive care unit. There also is a significant cost savings for the third party payer, especially if the patient has to wait a significant amount of time before heart transplantation. These are important considerations in this time of managed care.
Collapse
Affiliation(s)
- F A Arabia
- University of Arizona Health Sciences Center, Tucson 85724, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Arabia FA, Smith RG, Rose DS, Arzouman DA, Sethi GK, Copeland JG. Success rates of long-term circulatory assist devices used currently for bridge to heart transplantation. ASAIO J 1996; 42:M542-6. [PMID: 8944938 DOI: 10.1097/00002480-199609000-00045] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Circulatory assist devices as bridge to heart transplantation have become more important as the number of possible recipients has increased and the number of donors remains stable. The number of patients successfully bridged and discharged home after transplantation was determined for the Novacor Left Ventricular Assist System (Baxter Healthcare Corp., Oakland, CA) (LVAS), console and wearable; the TCI Left Ventricular Assist Device (Thermo Cardio Systems Inc., Woburn, MA) (LVAD), pneumatic and electric; the Thoratec LVAD and Biventricular Assist Device (Thoratec Lab Co., Berkeley, CA) (BIVAD); and the CardioWest total artificial heart (CardioWest Tech. Inc., Tuscon, AZ) (TAH). A total of 1,286 devices (14% Novacor console, 14% Novacor wearable, 35% TCI pneumatic, 4% TCI electric, 10% thoratec LVAD, 19% Thoratec BIVAD, and 4% CardioWest TAH) were implanted worldwide since 1984. A total of 776 (60%) patients reached heart transplantation and 687 patients (88.5% of those transplanted) were discharged home. The individual success rate for each device to bridge a patient to heart transplantation and be discharged home is as follows: Novacor LVAS console, 90%; Novacor LVAS wearable, 92%; TCI LVAD pneumatic, 89%; TCI LVAD electric, 89%; Thoratec LVAD, 93%; Thoratec BIVAD, 81%; and CardioWest TAH, 92%. The success rate with all the available systems to bridge a patient to heart transplantation and be discharged home is similar for all devices. The criteria used to determine which system to be used should be individualized for each patient. Some of the factors that should be considered in making a decision on which device to use should include anticoagulation, univentricular vs biventricular failure, mobility, protocol to discharge home, and size of the patient.
Collapse
Affiliation(s)
- F A Arabia
- University of Arizona, Health Sciences Center, Tucson 85724, USA
| | | | | | | | | | | |
Collapse
|
18
|
Abstract
Reconstruction was accomplished in a 2 heart-lung recipients with situs inversus resulting in a left-sided systemic venous atrium. We created a large common atrium that was closed on the left side, leaving an atrial cuff on the inferior right quadrant. To this we anastomosed the donor right atrium, which had been opened laterally between the cavae. This resulted in some clockwise rotation of the ventricles and anterior positioning of the apex. The right pulmonary veins passed superior to the atrial anastomosis and posterior to the donor right atrium. Cardiopulmonary function was excellent in both cases.
Collapse
Affiliation(s)
- G Rábago
- Department of Cardiovascular and Thoracic Surgery, University of Arizona, Tucson, USA
| | | | | | | | | | | | | |
Collapse
|
19
|
Copeland JG, Pavie A, Duveau D, Keon WJ, Masters R, Pifarre R, Smith RG, Arabia FA. Bridge to transplantation with the CardioWest total artificial heart: the international experience 1993 to 1995. J Heart Lung Transplant 1996; 15:94-9. [PMID: 8820088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND After reapproval by the Food and Drug Administration of the CardioWest total artificial heart for clinical investigation, an international study was started in January 1993 to ascertain the safety and efficacy of this device for bridging to heart transplantation. To date, 40 devices have been implanted in five centers. METHODS Retrospective data collection from participating centers provided enough material for analysis of patient selection, patient survival, adverse events, and comparison with contemporary devices used for bridge to transplantation. RESULTS AND CONCLUSIONS Twelve patients (30%) died after implantation and before transplantation after an average of 10.6 +/- 10 days of support. The major cause of death in this group was multiorgan failure. Twenty-eight patients (70%) were supported 36 +/- 36 days before transplantation. There were two deaths after transplantation (1 rejection, 1 multiorgan failure) leaving 26 patients (65% of the total patients and 93% of those who were transplanted) who survived to discharge from the hospital. There was one late death from rejection at one month post discharge. The mean survival time of the 25 surviving patients is 12 months. These results compare favorably with those of other contemporary devices used for bridge to transplantation.
Collapse
Affiliation(s)
- J G Copeland
- Cardiothoracic Surgery, University Heart Center, Tucson, AZ 85724, USA
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Sethi GK, Kosaraju S, Arabia FA, Roasdo LJ, McCarthy MS, Copeland JG. Is it necessary to perform surveillance endomyocardial biopsies in heart transplant recipients? J Heart Lung Transplant 1995; 14:1047-51. [PMID: 8719449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND Routine surveillance endomyocardial biopsies to diagnose unsuspected rejection are performed at 3- to 12-month intervals after heart transplantation. From 1979 to 1989, surveillance biopsies were routinely performed as a part of the yearly evaluation. METHODS A retrospective analysis of the follow-up data showed that "routine surveillance biopsies" had an extremely low yield, and, on the basis of the results of this study, we discontinued to perform surveillance biopsies beyond 6 months after transplantation. To validate these results, we compared the outcome of two groups of patients who had similar demographics and identical immunosuppression, except that in one group the surveillance biopsies were not performed. RESULTS No difference was found in either actuarial survival rate or freedom from late rejection between the two groups. CONCLUSIONS These findings confirm that routine surveillance heart biopsies beyond 6 months after transplantation are not necessary and they should be performed only if there is clinical suspicion of rejection or as part of a research protocol.
Collapse
Affiliation(s)
- G K Sethi
- Department of Surgery, University of Arizona, Tucson 85724, USA
| | | | | | | | | | | |
Collapse
|
21
|
Copeland JG, Tsau PH, Arabia FA, Xie T. Correlation of clinical embolic events with coagulability in a patient with a total artificial heart. J Heart Lung Transplant 1995; 14:990-8. [PMID: 8800738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
A 46-year-old female patient was supported for 185 days with a total artificial heart, underwent successful transplantation, and survived for over 1 year with no clinical residual findings suggestive of embolic events. Daily observation, analysis of a large battery of coagulation tests, and eight serial computed tomographic scans suggest that she had 12 embolic events while receiving mechanical support. Furthermore, it appears that the events were associated temporally with several mild infections and that coagulation was stimulated several days to 1 week before we detected the events.
Collapse
Affiliation(s)
- J G Copeland
- Section of Cardiovascular and Thoracic Surgery, University of Arizona, Tucson, USA
| | | | | | | |
Collapse
|
22
|
Abstract
Well-known complications of heart-lung transplantation include mediastinal bleeding and phrenic nerve injury. Conventional technique places the hila behind the phrenic nerves. We have placed the hila in front of the phrenic nerve in our last 10 patients, using direct caval anastomoses when feasible. This minimizes traction on and dissection around the phrenic nerves, and allows anterior rotation of the heart-lung block for easier hemostasis of the posterior mediastinum after implantation.
Collapse
Affiliation(s)
- S D Lick
- Department of Cardiothoracic Surgery, University of Arizona, Tucson, USA
| | | | | | | | | |
Collapse
|
23
|
Rosado LJ, Arabia FA, Smith RG, Copeland JG. Cardiovascular assist devices. Acad Radiol 1995; 2:418-27. [PMID: 9419585 DOI: 10.1016/s1076-6332(05)80347-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- L J Rosado
- Division of Cardiovascular and Thoracic Surgery, University of Arizona Heart Center, Tucson, USA
| | | | | | | |
Collapse
|
24
|
Arabia FA, Rosado LJ, Lloyd TR, Sethi GK. Management of complications of Sideris transcatheter devices for atrial septal defect closure. J Thorac Cardiovasc Surg 1993; 106:886-8. [PMID: 8231212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Various devices that can be inserted transvenously to close an ostium secundum atrial septal defect are undergoing clinical trials. Although these are safe and effective in most instances, they may occasionally dislodge or fail to "button" properly, causing migration and embolization. We report two cases in which the occluder and counteroccluder of the Sideris device for transvenous atrial septal defect occlusion (Custom Medical Devices, Amarillo, Tex.) failed to "button" appropriately, migrating in the right atrium in one patient and embolizing to the pulmonary artery in the second patient. An emergency operation was required to retrieve the device and repair the atrial septal defect.
Collapse
Affiliation(s)
- F A Arabia
- Section of Cardiovascular and Thoracic Surgery, University of Arizona Health Sciences Center, Tucson 85724
| | | | | | | |
Collapse
|
25
|
Arabia FA, Copeland JG, Smith RG. Progress on the total artificial heart. Surg Technol Int 1993; 2:251-254. [PMID: 25951571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The total artificial heart (TAH) is a device that fully replaces the failing heart and provides control of the circulatory system. This device has been used to provide permanent support, however, its most important role is to serve as a bridge to cardiac transplantation. There are two of these devices available: the CardioWest C-70TM (Symbion, Jarvik J-7™) and the Penn State Heart. The TAH replaces the ventricles and is anastomosed to the respective atria and great vessels. It is constructed of segmental polyurethane and utilizes mechanical heart valves for inflow and outflow. It connects to a console via drive lines that pierce the skin, The TAH is pneumatically driven, and a personal computer monitors its function. Its advantages include control of the circulatory system, reversal of early organ failure, and early mobility of the patient. Its disadvantages include cost, and the complications of infection and thromboembolism. Further investigation of this device is required to develop an optimal total artificial heart.
Collapse
Affiliation(s)
- F A Arabia
- Section of Cardiovascular and Thoracic Surgery, The University of Arizona Heart Center, Tucson, Arizona
| | - J G Copeland
- Section of Cardiovascular and Thoracic Surgery, The University of Arizona Heart Center, Tucson, Arizona
| | - R G Smith
- Artificial Heart Program, University Medical Center, Tucson, Arizona
| |
Collapse
|
26
|
Abstract
Cytomegalovirus (CMV) infection of the upper gastrointestinal tract is a major cause of morbidity in heart transplant recipients. Since April 1985, 201 patients underwent heart transplantation at our institution. Immunosuppressive therapy was with a triple drug regimen of cyclosporin A, prednisone, and azathioprine. Fifty-three of these patients had upper gastrointestinal symptoms, which primarily consisted of abdominal pain or nausea and vomiting despite prophylactic treatment with antacids, H2 blockers, or both. A total of 79 esophagogastroduodenoscopies were performed in this group; 15 patients required more than one esophagogastroduodenoscopy for recurrent symptoms. Of these 53 patients with persistent gastrointestinal symptoms, 16 (30.2%) had diffuse erythema or ulceration of the gastric mucosa (14), esophagus (1), and duodenum (1) with biopsy results that were positive for CMV on viral cultures (incidence, 8%). All patients with positive biopsy results were treated with intravenous ganciclovir at a dose of 10 mg.kg-1.day-1 in two divided doses for a period of 2 weeks. Recurrence developed in 6 patients (37.5%) and necessitated repeated therapy with ganciclovir. None of the 16 patients died as a result of gastrointestinal CMV infection. Patients who were seronegative for CMV and received a seropositive heart experienced earlier clinical manifestation of CMV infection. Infection of the upper gastrointestinal tract with CMV is a major cause of morbidity in cardiac transplant patients that may progress to a life-threatening complication if left untreated. Early diagnosis with esophagogastroduodenoscopy and biopsy for viral cultures is essential for documentation and proper management.
Collapse
Affiliation(s)
- F A Arabia
- Section of Cardiovascular and Thoracic Surgery, University of Arizona College of Medicine, Tucson 85724
| | | | | | | | | |
Collapse
|
27
|
Stewart SF, Nast EP, Arabia FA, Talbot TL, Proschan M, Clark RE. Errors in pressure gradient measurement by continuous wave Doppler ultrasound: type, size and age effects in bioprosthetic aortic valves. J Am Coll Cardiol 1991; 18:769-79. [PMID: 1869741 DOI: 10.1016/0735-1097(91)90801-f] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The accuracy of continuous wave Doppler ultrasound in deriving pressure gradients across bioprosthetic heart valves was evaluated in an in vitro pulse duplicator. Simultaneous pressure transducer and Doppler measurements were made in new and explanted aortic bioprosthetic valves of several sizes and four types: Carpentier-Edwards, Ionescu-Shiley, Hancock standard and Hancock modified. The mean and peak gradients calculated by the modified Bernoulli equation from Doppler velocity measurements were always greater than those measured manometrically, despite corrections for location dependence of the manometric gradient (or pressure recovery). The relation between manometric and ultrasonically determined gradient was found to be statistically dependent on the valve type (mean gradient p less than 0.0001; peak gradient p = 0.0003) and size (mean gradient p = 0.0089; peak gradient p = 0.0107). Effects of implantation were observed, but were not shown to be significant. It is concluded that the continuous wave Doppler velocity data overestimated prosthetic valve pressure gradient in all cases, even when pressure recovery was taken into account. Clinicians should be wary of Doppler data when making major diagnostic or therapeutic decisions.
Collapse
Affiliation(s)
- S F Stewart
- Cardiac Surgery and Biostatistics Branches, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | | | | | | | | | | |
Collapse
|
28
|
Arabia FA, Talbot TL, Stewart SF, Nast EP, Clark RE. A computerized physiologic pulse duplicator for in-vitro hydrodynamic and ultrasonic studies of prosthetic heart valves. Biomed Instrum Technol 1989; 23:205-15. [PMID: 2752231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
A physiologic pulse duplicator for the simultaneous in-vitro hydrodynamic and ultrasonic evaluation of aortic prosthetic heart valves is described. The system is interfaced to a personal computer, which provides greater efficiency over manual techniques in system calibration, data acquisition, and analysis. The data analysis program aids selection of start and end systole and calculates pressure difference across the valve, the closing and regurgitant volumes, flow rates, and the Gabbay and Swanson performance indices. The pulse duplicator is designed to accommodate the ultrasonic measurement of fluid velocities, including pressure difference via the Bernoulli equation, and color-flow imaging. In tests of 19-mm, 23-mm, and 27-mm Bjork-Shiley spherical occluder valves, continuous-wave Doppler ultrasound was found to overestimate by about 50% the pressure difference measured directly by pressure transducers, a finding that is clinically important.
Collapse
Affiliation(s)
- F A Arabia
- Cardiac Surgery Branch, National Institutes of Health, Bethesda, Maryland 20892
| | | | | | | | | |
Collapse
|